Compare Novavax Inc (NVAX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Global X SuperDividend ETF — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Global X SuperDividend ETF trades at $24.87. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SDIV | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $26.34 |
52-Week Low | $6.22 | $22.90 |
Enterprise Value | $800.50M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
